Table 1 Patient demographics and clinical characteristics
TPF(n = 772) | PF(n = 340) | TP(n = 242) | |||
|---|---|---|---|---|---|
Characteristics | No. (%) | No. (%) | No. (%) | No. (%) | P value |
Age, years | 0.307a | ||||
Median (range) | 44(8–74) | 43(8–74) | 44(15–71) | 46(18–71) | |
< 45 | 698(51.6) | 411(53.2) | 171(50.3) | 116(47.9) | |
≥ 45 | 656(48.4) | 361(46.8) | 169(49.7) | 126(52.1) | |
Sex | 0.580a | ||||
Female | 335(24.7) | 184(23.8) | 91(26.8) | 60(24.8) | |
Male | 1019(75.3) | 588(76.2) | 249(73.2) | 182(75.2) | |
Pathological type | 0.217b | ||||
WHO type I | 4(0.3) | 3(0.4) | 1(0.3) | 0(0.0) | |
WHO type II | 9(0.7) | 4(0.5) | 5(1.5) | 0(0.0) | |
WHO type III | 1341(99.0) | 765(99.1) | 334(98.2) | 242(100) | |
T stagec | 0.199a | ||||
T1 | 18(1.3) | 11(1.4) | 5(1.5) | 2(0.8) | |
T2 | 149(11.0) | 71(9.2) | 49(14.4) | 29(12.0) | |
T3 | 665(49.1) | 379(49.1) | 168(49.4) | 118(48.8) | |
T4 | 522(38.6) | 311(40.3) | 118(34.7) | 93(38.4) | |
N stagec | < 0.001a | ||||
N0 | 35(2.6) | 15(1.9) | 11(3.2) | 9(3.7) | |
N1 | 315(23.3) | 193(25.0) | 57(16.8) | 65(26.9) | |
N2 | 695(51.3) | 367(47.5) | 197(57.9) | 131(54.1) | |
N3 | 309(22.8) | 197(25.5) | 75(22.1) | 37(15.3) | |
Clinical stagec | 0.005a | ||||
III | 612(45.2) | 320(41.5) | 167(49.1) | 125(51.7) | |
IVa-b | 742(54.8) | 452(58.5) | 173(50.9) | 117(48.3) | |
EBV DNA | < 0.001a | ||||
≥ 1500 | 875(64.6) | 514 (66.6) | 231(67.9) | 130(53.7) | |
< 1500 | 479(35.4) | 258 (33.4) | 109(32.1) | 112(46.3) | |
RT technique | < 0.001a | ||||
2D RT | 119(8.8) | 7(0.9) | 101(29.7) | 11(4.5) | |
IMRT | 1235(91.2) | 765(99.1) | 239(70.3) | 231(95.5) | |
CCD (mg/m2) | 0.127a | ||||
Median (range) | 160(20–300) | 160(25–300) | 160(40–250) | 160(20–300) | |
≥ 200 | 295(21.8) | 183(23.7) | 63(18.5) | 49(20.2) | |
< 200 | 1059(78.2) | 589(76.3) | 277(81.5) | 193(79.8) | |